炎症性肠病患者对乙型肝炎疫苗接种的免疫应答:系统综述与Meta分析
该系统综述与Meta分析检索PubMed、Cochrane图书馆和Embase数据库至2016年7月,纳入13项研究共1688例炎症性肠病患者,评估乙型肝炎疫苗接种后的应答率及预测因素。随机效应模型合并应答率为61%(95%CI:53-69);年轻年龄和疾病缓解期接种与阳性应答相关,未使用免疫抑制治疗者应答优于免疫调节剂或抗TNF-α治疗者。
要点
- 炎症性肠病患者乙肝疫苗接种合并应答率为61%(95%CI:53-69)。
- 疾病缓解期接种者应答率为活动期的1.62倍(RR 1.62,95%CI:1.15-2.29)。
- 未用免疫抑制剂者应答优于免疫调节剂(RR 1.33)或抗TNF-α(RR 1.57)治疗者。
核心结论
- 基于该Meta分析,约五分之三的炎症性肠病患者对乙型肝炎疫苗产生血清学应答。
- 作者建议在炎症性肠病诊断时、疾病缓解期或开始免疫抑制治疗前接种乙型肝炎疫苗。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Cochrane图书馆和Embase数据库至2016年7月,纳入13项研究共1688例炎症性肠病患者。
- 抗-HBs水平>10 IU/L定义为有效免疫应答,主要结局为完成系列接种后的应答率。
主要发现
- 随机效应模型合并的炎症性肠病患者乙型肝炎疫苗应答率为61%(95%CI:53-69)。
- 年轻年龄与阳性应答相关(均数差MD:-5.7;95%CI:-8.46,-2.95)。
- 疾病缓解期接种与阳性应答相关(相对危险度RR:1.62;95%CI:1.15-2.29)。
- 与免疫调节剂治疗相比,未使用免疫抑制治疗预测免疫应答(RR:1.33;95%CI:1.08-1.63)。
- 与抗肿瘤坏死因子-α(抗TNF-α)治疗相比,未使用免疫抑制治疗预测免疫应答(RR:1.57;95%CI:1.19-2.08)。
关键数值与推荐
- 抗-HBs水平>10 IU/L视为有效免疫应答。
- 合并应答率61%(95%CI:53-69)。
- 年轻年龄的均数差MD:-5.7(95%CI:-8.46,-2.95)。
- 疾病缓解期接种的RR:1.62(95%CI:1.15-2.29)。
- 未使用免疫抑制治疗 vs 免疫调节剂治疗的RR:1.33(95%CI:1.08-1.63);vs 抗TNF-α治疗的RR:1.57(95%CI:1.19-2.08)。
临床怎么用
- 作者建议在炎症性肠病诊断时、疾病缓解期或开始免疫抑制治疗前接种乙型肝炎疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The response rate to hepatitis B virus (HBV) vaccination in patients with inflammatory bowel disease (IBD) is low and varies markedly. We performed a systematic review and meta-analysis to determine the response rate to HBV vaccination and identified the factors predictive of an immune response. METHODS: We searched PubMed, Cochrane Library, and Embase databases, and reviewed the titles and abstracts of studies on the efficacy of HBV vaccination in IBD patients performed through July 2016. Anti-HBs levels>10IU/L was considered to be an effective immune response. The primary outcome measure was the response rate to HBV vaccination after series completion, and the secondary outcome was identification of factors at baseline predictive of an immune response. RESULTS: Thirteen studies including 1688 patients were eligible for inclusion. Based on a random-effects model, the pooled rate of a response to HBV vaccination among patients with IBD was 61% (95% confidence interval [CI]: 53-69). Young age (mean difference [MD]: -5.7; 95% CI: -8.46, -2.95) and vaccination during disease remission (relative risk [RR]: 1.62; 95% CI: 1.15-2.29) were associated with a positive response to HBV vaccination. In addition, no immunosuppressive therapy was predictive of an immune response compared to immunomodulatory (RR: 1.33; 95% CI: 1.08-1.63) or anti-tumor necrosis factor-α (anti-TNF-α) (RR: 1.57; 95% CI: 1.19-2.08) therapy. CONCLUSIONS: Based on this meta-analysis, only three of five IBD patients will show a serological response to HBV vaccination. Vaccination should be performed at the time of IBD diagnosis, during disease remission, or before starting immunosuppressive therapy.
引用
- Jiang HY, Wang SY, Deng M, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis. Vaccine. 2017. PMID: 28404358. doi:10.1016/j.vaccine.2017.03.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。